Most Read Articles
Dr Margaret Shi, 13 Jul 2020

An MRI-first diagnostic pathway, combined with risk-tailored screening, is shown to improve the benefit-to-harm profile and cost-effectiveness of screening for prostate cancer (PCa), according to results of a recent lifetable modelling study presented at AACR 2020 Virtual Meeting II.

Christina Lau, 14 Jul 2020

Flat-dose nivolumab, administered as a 30-minute infusion, is well tolerated and active in Asian patients with previously treated advanced non-small-cell lung cancer (NSCLC), according to results of the phase IIIb CheckMate 870 study.

Natalia Reoutova, 17 Jul 2020

At a median follow-up of 22.9 months, atezolizumab plus carboplatin and etoposide (CP/ET), given as a first-line treatment, continued to demonstrate an improvement in overall survival (OS) vs placebo plus CP/ET in patients with extensive-stage small-cell lung cancer (ES-SCLC), according to updated results of the IMpower133 trial presented at the American Association for cancer Research (AACR) 2020 Virtual Annual Meeting II.

13 Feb 2020
At the recent National Haematology Expert Meeting 2019, a panel of experts was convened to discuss the role of targeted therapy in the management of haematological malignancies. Highlights of their lectures are summarised below.

Liquid biopsy promising for multidrug resistance detection in multiple myeloma

Jairia Dela Cruz
04 May 2020

Liquid biopsy may facilitate detection and serial monitoring of multidrug resistance (MDR) in multiple myeloma by analysing multiparticles (MPs) in blood samples of patients, with a recent study showing that MDR markers are found on MPs of stem-cell-like origin.

“One of the most important mechanisms by which cancers acquire MDR is through the overexpression of resistance proteins, belonging to the ATP class of drug transporters, including P-glycoprotein (P-gp). These are plasma membrane drug efflux transporters that mediate the removal of chemotherapeutics from the cancer cell plasma membrane,” researchers said. [Int J Mol Sci 2017;18:2362]

“We discovered that cancer-derived MPs confer the transfer and spread of MDR within cancer cell populations through the intercellular transfer of functional resistance proteins and nucleic acids packaged within the vesicular cargo,” they added. [Pharmacol Res 2013;76:77-83; Mol Cancer 2012;11:37; Leukemia 2009;23:1643-1649]

In the current study, the researchers immunophenotyped MPs (or circulating large extracellular vesicles) isolated from patients for the presence of four protein biomarkers useful for monitoring MDR development, disease burden and disease progression in multiple myeloma. These biomarkers were the MDR protein P-gp, the plasma-cell marker CD138, the stem-cell marker CD34, and the MP marker and mediator of cancer spread phosphatidylserine (PS).

Three markers (P-gp, CD138, PS) were evaluated independently in 74 patients, among whom 42 were treatment responsive (partial remission, n=30; complete remission, n=12), 14 had de novo disease and 18 had a relapse. The complete signature comprising four markers (P-gp, CD138, PS, CD34) was assessed in 11 patients.

Results revealed that elevated levels of P-gp+ and PS+ MPs were associated with disease progression and treatment unresponsiveness. P-gp, PS and CD34 proteins were predominantly expressed in CD138 MPs in advanced disease. Of note, a dual-positive (CD138P-gp+CD34+) MP was elevated in aggressive/unresponsive disease. [Blood Cancer J 2020;10:37]

“In conclusion, MPs provide a surrogate marker of their cells of origin, which in the case of myeloma are predominantly confined to the bone marrow… Our results indicate the presence of markers of MDR on MPs of stem-cell-like origin. Stem cells are a reservoir of P-gp-positive cells, the levels of which appear to correspond to disease progression,” the researchers pointed out.

Minimally invasive personalized liquid biopsy accounts for tumour heterogeneity characteristic of multisite tumour infiltrates, can detect the presence of MDR during routine follow-up, and allows for simultaneous analysis of disease burden, according to the researchers.

The test may be used as a complement to existing gold standard tests, supporting clinical staging criteria and streamlining easily into existing hospital workflows, they added.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Dr Margaret Shi, 13 Jul 2020

An MRI-first diagnostic pathway, combined with risk-tailored screening, is shown to improve the benefit-to-harm profile and cost-effectiveness of screening for prostate cancer (PCa), according to results of a recent lifetable modelling study presented at AACR 2020 Virtual Meeting II.

Christina Lau, 14 Jul 2020

Flat-dose nivolumab, administered as a 30-minute infusion, is well tolerated and active in Asian patients with previously treated advanced non-small-cell lung cancer (NSCLC), according to results of the phase IIIb CheckMate 870 study.

Natalia Reoutova, 17 Jul 2020

At a median follow-up of 22.9 months, atezolizumab plus carboplatin and etoposide (CP/ET), given as a first-line treatment, continued to demonstrate an improvement in overall survival (OS) vs placebo plus CP/ET in patients with extensive-stage small-cell lung cancer (ES-SCLC), according to updated results of the IMpower133 trial presented at the American Association for cancer Research (AACR) 2020 Virtual Annual Meeting II.

13 Feb 2020
At the recent National Haematology Expert Meeting 2019, a panel of experts was convened to discuss the role of targeted therapy in the management of haematological malignancies. Highlights of their lectures are summarised below.